Evoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report released on Sunday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Down 7.7 %

Shares of EVOK stock opened at $5.07 on Friday. The firm has a market capitalization of $7.53 million, a price-to-earnings ratio of -0.46 and a beta of 0.16. The stock has a fifty day moving average of $4.95 and a 200 day moving average of $5.30. Evoke Pharma has a 52 week low of $3.54 and a 52 week high of $14.16.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.